TuHURA Biosciences, Inc. HURA
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
TuHURA Biosciences, Inc. (HURA) is a healthcare company listed in the US with a market value of about $89M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
About TuHURA Biosciences
TuHURA Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 3 of the last 10 years in our data. Its share count rose by 4821% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — | — | — | — | — | — | — |
| Net income | -$30M | -$22M | -$29M | -$23M | -$38M | -$9M | -$8M | $11M | $8M | $9M |
| Free cash flow | -$28M | -$15M | -$12M | -$21M | -$19M | -$8M | -$6M | -$10M | -$8M | -$5M |
| EPS (diluted) | $-0.63 | $-1.21 | $-2.47 | $-25.80 | $-80.00 | $-43.50 | $158.01 | $271.01 | $370.02 | $415.02 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | — | — | — | — | — | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $8.04, 478% above the current price; targets range from $6.20 to $10.00; the consensus rating is “Strong buy”; expected EPS is $-0.49 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does TuHURA Biosciences pay a dividend?
Not currently.
Is TuHURA Biosciences a good stock to buy?
We do not give buy or sell advice. TuHURA Biosciences scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.